Compare GSK plc (GSK) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Sibanye Stillwater Ltd — how do they compare? GSK plc trades at $52.74 (market cap $101.34B), while Sibanye Stillwater Ltd trades at $8.11 (market cap $5.93B). The key difference: GSK plc is far larger — about 17.1× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (3.64%). Which is the better fit depends on your goals.
| GSK | SBSW | |
|---|---|---|
Market Cap | $101.34B | $5.93B |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $21.12 |
52-Week Low | $36.20 | $7.27 |
Enterprise Value | $121.95B | $7.56B |
Dividend Yield | 3.49% | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Sibanye Stillwater (SBSW) trades at $8.12, down 5.25% today, reflecting ongoing challenges despite a low P/E of 4.76 and P/S of 0.77. The stock shows bearish technical signals with key support at $8, while fundamentals reveal negative net income margins and ROE. Recent news highlights operational improvements, including a surge in EBITDA and management's debt reduction targets, yet earnings misses in recent quarters underscore persistent profitability issues.
The outlook is mixed: deep valuation discounts and analyst consensus targets near $14.25 suggest upside potential, but risks from volatile commodity prices, high debt, and inconsistent earnings warrant caution. Investors should weigh the turnaround narrative against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
